This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +22.98% per year. These returns cover a period from January 1, 1988 through April 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Analyst Blog: Archive
CRDO Tanks 33% in 3 Months: Should You Hold the Stock or Make an Exit?
by Vaishali Doshi
CRDO is gaining from an innovative portfolio and expanding AI-driven market opportunities, but does the recent stock dip spell trouble, or is it an opportunity?
MRVLPositive Net Change AVGOPositive Net Change CRUSPositive Net Change CRDOPositive Net Change
tech-stocks
Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline
by Zacks Equity Research
SOLV's first-quarter earnings showcase strong segmental performance. However, declining margins raise concerns.
CAHPositive Net Change CVSNegative Net Change AXGNPositive Net Change SOLVPositive Net Change
earnings medical medical-devices
Sensata's Q1 Earnings & Revenues Surpass Estimates, Down Y/Y
by Zacks Equity Research
ST's first-quarter 2025 performance reflects improvement in Sensing Solutions business, while Performance Sensing witnesses a slowdown.
BMIPositive Net Change ITRIPositive Net Change STPositive Net Change WTSPositive Net Change
tech-stocks
Choice Hotels Q1 Earnings Lag Estimates, FY25 View Trimmed, Stock Down
by Zacks Equity Research
CHH's first-quarter results are aided by a more balanced growth model, a stronger customer base and an expanded brand portfolio.
CHHPositive Net Change WWPositive Net Change BALYNegative Net Change SRADPositive Net Change
consumer-discretionary
Buy These 5 Cloud Computing Stocks to Strengthen Your Portfolio
by Nalak Das
Five cloud-computing stocks have strong earnings and revenue growth potential for 2025. These are: FIVN, AFRM, MSFT, JNPR, TYL.
MSFTPositive Net Change JNPRPositive Net Change FIVNPositive Net Change TYLPositive Net Change AFRMPositive Net Change
computers internet tech-stocks
MCK Stock Up on Q4 Earnings Beat & Potential Surgical Biz Spin-Off
by Zacks Equity Research
McKesson's fourth-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
CAHPositive Net Change MCKNegative Net Change CVSNegative Net Change AXGNPositive Net Change
earnings medical medical-devices
Here's Why You Should Retain Adient Stock in Your Portfolio Now
by Zacks Equity Research
ADNT is poised to gain from its broad range of products and frequent business wins despite headwinds from higher restructuring costs in Europe.
SMPPositive Net Change ADNTPositive Net Change HSAIPositive Net Change
auto-tires-trucks electric-vehicles
Plains All American Q1 Earnings Miss Estimates, Sales Increase Y/Y
by Zacks Equity Research
PAA's first-quarter 2025 earnings decrease year over year, while revenues increase.
PAAPositive Net Change OKEPositive Net Change CNXNegative Net Change MURPositive Net Change
oil-energy
Papa John's Q1 Earnings & Revenues Beat Estimates, Stock Up
by Zacks Equity Research
PZZA's Q1 top line reflects a gain in commissary revenues, stemming from higher commodity prices. Also, a rise in advertising funds adds to the positives.
YUMNegative Net Change DPZPositive Net Change EATPositive Net Change PZZAPositive Net Change
earnings restaurants retail
Post Holdings Q2 Earnings Beat Estimates, FY25 Outlook Raised
by Zacks Equity Research
POST's fiscal second-quarter results show a year-over-year sales decline, due to mixed segment trends. Management raises its 2025 outlook.
BRFSPositive Net Change UNFIPositive Net Change MDLZNegative Net Change POSTNegative Net Change
consumer-staples earnings
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
by Zacks Equity Research
NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall in after-hours trading.
LLYPositive Net Change NKTRPositive Net Change ANIPNegative Net Change NTLAPositive Net Change
earnings medical
Brighthouse Financial Q1 Earnings Miss Estimates on Higher Expenses
by Zacks Equity Research
BHF's first-quarter results reflect lower premiums and escalating expenses, offset by improved adjusted net investment income.
MFCPositive Net Change RGAPositive Net Change VOYAPositive Net Change BHFPositive Net Change
insurance
Here's Why Hold Strategy is Apt for Kinder Morgan Stock Now
by Zacks Equity Research
KMI generates stable fee-based revenues from its vast network of midstream infrastructure. However, a slowdown in drilling activities might affect it.
WMBNegative Net Change EPDPositive Net Change ENBNegative Net Change KMINegative Net Change
oil-energy
Is ConocoPhillips Stock Still Worth Owning After Strong Q1 Earnings?
by Nilanjan Banerjee
COP has a strong production outlook, backed by its decades of low-cost inventory of drilling sites.
BPPositive Net Change CVXPositive Net Change COPPositive Net Change
oil-energy
Is CEG Stock Worth Investing in After In-Line Q1 Earnings?
by Tanvi Sarawagi
CEG is a good stock to add in your portfolio, given its rising earnings estimates and increasing demand for clean energy in its service territories.
CEGPositive Net Change DUKNegative Net Change VSTPositive Net Change
oil-energy
CVNA Q1 Earnings Beat on Solid Revenues, Adjusted EBITDA Doubles
by Zacks Equity Research
Solid revenues across segments lead to CVNA's first-quarter outperformance. It expects a rise in retail units sold and adjusted EBITDA in the second quarter.
ANPositive Net Change SAHPositive Net Change LADPositive Net Change CVNAPositive Net Change
auto-tires-trucks
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
by Zacks Equity Research
Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.
SNYPositive Net Change NVAXPositive Net Change BEAMPositive Net Change ADPTPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update
by Kinjel Shah
NVO and JAZZ report first-quarter results. AZN's asthma study on Breztri meets key goals.
AZNPositive Net Change NVOPositive Net Change JAZZPositive Net Change
pharmaceuticals
Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips
by Zacks Equity Research
ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025.
BSXNegative Net Change ANGOPositive Net Change ILMNPositive Net Change ITGRPositive Net Change
earnings medical medical-devices
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Puma Biotechnology beats on first-quarter 2025 earnings and sales. Stock rises in after-hours trading
PBYIPositive Net Change ANIPNegative Net Change ADMAPositive Net Change IMCRPositive Net Change
biotechs
4 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Stocks like TGI, HRTG, ATRO and DB are seeing price strength and have a high chance of carrying the momentum forward.
TGIPositive Net Change DBPositive Net Change ATROPositive Net Change HRTGNegative Net Change
aerospace finance
BCE's Q1 Earnings Top Despite Lower Revenues, Stock Gains on PSP Deal
by Zacks Equity Research
BCE's Q1 2025 results reflect pricing and regulatory pressures amid macro and geopolitical turmoil. It announces a partnership with PSP Investments.
BMIPositive Net Change BCENegative Net Change CDNSPositive Net Change WWDPositive Net Change
communications earnings tech-stocks utilities
Onto Innovation's Q1 Earnings Beat on Solid Y/Y Top-Line Improvement
by Zacks Equity Research
ONTO posts record Q1 revenues of $267 million - its 7th consecutive quarter of sales growth - driven by momentum in advanced nodes and AI packaging markets.
BMIPositive Net Change CDNSPositive Net Change WWDPositive Net Change ONTOPositive Net Change
earnings tech-stocks
FUJIFILM's Q4 Earnings and Revenues Increase Y/Y, Margins Expand
by Zacks Equity Research
FUJIY???s Q4 earnings and revenues grow year over year, driven by robust sales growth across all segments.
MSFTPositive Net Change BMIPositive Net Change INFYPositive Net Change FUJIYPositive Net Change
earnings tech-stocks
5 Low Price-to-Sales Stocks That Deserve a Place in Your Portfolio
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like PCB, GIII, ROCK, PFE and PAM hold promise.
PFEPositive Net Change PAMPositive Net Change GIIIPositive Net Change ROCKPositive Net Change PCBPositive Net Change
construction consumer-discretionary finance medical utilities